A New Oral Treatment For Type II Diabetes Mellitus

• Status: Completed
• Trial end date: 2006-07-21
• Target enrollment: 0
• Participant gender: All

Summary

This is a 24-week study investigating the safety and efficacy of several dosages of a potential new oral medicine for Type II diabetes mellitus.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline

Criteria

Inclusion criteria:

• Women must not be pregnant and must not be breastfeeding.

• Have Type II diabetes.

• Not taking any medicine for diabetes, or taking one oral medicine for their diabetes.

Exclusion criteria:

• Have any underlying or significant active disease that would prevent the subject from safely participating in the trial by the judgement of the study doctor.